BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 12641522)

  • 1. High eradication rates of Helicobacter pylori with a new sequential treatment.
    Zullo A; Vaira D; Vakil N; Hassan C; Gatta L; Ricci C; De Francesco V; Menegatti M; Tampieri A; Perna F; Rinaldi V; Perri F; Papadìa C; Fornari F; Pilati S; Mete LS; Merla A; Potì R; Marinone G; Savioli A; Campo SM; Faleo D; Ierardi E; Miglioli M; Morini S
    Aliment Pharmacol Ther; 2003 Mar; 17(5):719-26. PubMed ID: 12641522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia.
    De Francesco V; Della Valle N; Stoppino V; Amoruso A; Muscatiello N; Panella C; Ierardi E
    Aliment Pharmacol Ther; 2004 May; 19(9):993-8. PubMed ID: 15113366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study.
    Zullo A; Gatta L; De Francesco V; Hassan C; Ricci C; Bernabucci V; Cavina M; Ierardi E; Morini S; Vaira D
    Aliment Pharmacol Ther; 2005 Jun; 21(12):1419-24. PubMed ID: 15948808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study.
    De Francesco V; Zullo A; Hassan C; Della Valle N; Pietrini L; Minenna MF; Winn S; Monno R; Stoppino V; Morini S; Panella C; Ierardi E
    Dig Liver Dis; 2004 May; 36(5):322-6. PubMed ID: 15191200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy.
    Wang HH; Chou JW; Liao KF; Lin ZY; Lai HC; Hsu CH; Chen CB
    World J Gastroenterol; 2005 Mar; 11(11):1680-4. PubMed ID: 15786549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease.
    Hawkey CJ; Atherton JC; Treichel HC; Thjodleifsson B; Ravic M
    Aliment Pharmacol Ther; 2003 Apr; 17(8):1065-74. PubMed ID: 12694089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy.
    Hassan C; De Francesco V; Zullo A; Scaccianoce G; Piglionica D; Ierardi E; Panella C; Morini S
    Aliment Pharmacol Ther; 2003 Sep; 18(6):641-6. PubMed ID: 12969091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study.
    Gambaro C; Bilardi C; Dulbecco P; Iiritano E; Zentilin P; Mansia C; Usai P; Vigneri S; Savarino V
    Dig Liver Dis; 2003 Nov; 35(11):763-7. PubMed ID: 14674665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia.
    Lamouliatte H; Samoyeau R; De Mascarel A; Megraud F
    Aliment Pharmacol Ther; 1999 Nov; 13(11):1523-30. PubMed ID: 10571611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy.
    Nagahara A; Miwa H; Ogawa K; Kurosawa A; Ohkura R; Iida N; Sato N
    Helicobacter; 2000 Jun; 5(2):88-93. PubMed ID: 10849057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole.
    Giannini EG; Bilardi C; Dulbecco P; Mamone M; Santi ML; Testa R; Mansi C; Savarino V
    J Clin Gastroenterol; 2006 Jul; 40(6):515-20. PubMed ID: 16825934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration.
    Stack WA; Knifton A; Thirlwell D; Cockayne A; Jenkins D; Hawkey CJ; Atherton JC
    Am J Gastroenterol; 1998 Oct; 93(10):1909-13. PubMed ID: 9772054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
    Miki I; Aoyama N; Sakai T; Shirasaka D; Wambura CM; Maekawa S; Kuroda K; Tamura T; Kita T; Sakaeda T; Okumura K; Kasuga M
    Eur J Gastroenterol Hepatol; 2003 Jan; 15(1):27-33. PubMed ID: 12544691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open, randomized multicenter comparative trial of rabeprazole, ofloxacin and amoxicillin therapy for Helicobacter pylori eradication: 7 vs. 14 day treatment.
    Bosques-Padilla FJ; Garza-González E; Calderón-Lozano IE; Reed-SanRoman G; de Ariño Suárez M; Valdovinos-Díaz MA; Orozco-Gámiz A; Blancas-Valencia JM; Tamayo-de la Cuesta JL
    Helicobacter; 2004 Oct; 9(5):417-21. PubMed ID: 15361080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin.
    Kawabata H; Habu Y; Tomioka H; Kutsumi H; Kobayashi M; Oyasu K; Hayakumo T; Mizuno S; Kiyota K; Nakajima M; Kimoto K; Inokuchi H; Kawai K
    Aliment Pharmacol Ther; 2003 Jan; 17(2):259-64. PubMed ID: 12534411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori eradication in inactive peptic ulcer disease and the efficiency of sequential therapy in inactive peptic ulcer disease and non-ulcer dyspepsia.
    Chan CC; Chien NH; Lee CL; Yang YC; Hung CS; Tu TC; Wu CH
    BMC Gastroenterol; 2015 Dec; 15():170. PubMed ID: 26635102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori.
    De Francesco V; Margiotta M; Zullo A; Hassan C; Troiani L; Burattini O; Stella F; Di Leo A; Russo F; Marangi S; Monno R; Stoppino V; Morini S; Panella C; Ierardi E
    Ann Intern Med; 2006 Jan; 144(2):94-100. PubMed ID: 16418408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer.
    Yang KC; Wang GM; Chen JH; Chen TJ; Lee SC
    J Formos Med Assoc; 2003 Dec; 102(12):857-62. PubMed ID: 14976565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of a triple therapy with rabeprazole, amoxicillin, and faropenem as second-line treatment after failure of initial Helicobacter pylori eradication therapy.
    Togawa J; Inamori M; Fujisawa N; Takahashi H; Yoneda M; Kawamura H; Abe Y; Kirikoshi H; Kobayashi N; Sakaguchi T; Takamura T; Nakajima A; Ueno N; Sekihara H
    Hepatogastroenterology; 2005; 52(62):645-8. PubMed ID: 15816496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection.
    Cammarota G; Cianci R; Cannizzaro O; Cuoco L; Pirozzi G; Gasbarrini A; Armuzzi A; Zocco MA; Santarelli L; Arancio F; Gasbarrini G
    Aliment Pharmacol Ther; 2000 Oct; 14(10):1339-43. PubMed ID: 11012480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.